Company Profile
Invion Limited, a clinical-stage life sciences company researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers human papilloma virus.
It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer for the treatment of oesophageal cancer.
Incorporated in 2000, The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion is headquartered in Melbourne, Australia.